Chemical process of Action mechanism

COX-2 inhibitors simple machine the activeness of an enzyme that many tissues throughout the body utilize to make prostanoids, compounds that play a role in regulating an directional antenna of physiologic actions, such as rousing, roue clotting, and aegis of the tum protective cover from the destructive effects of digestive acids.
Ternion coxibs – celecoxib ( Celebrex ; Pfizer), rofecoxib ( Vioxx ), and valdecoxib ( Bextra ; Pfizer) – have been approved for use by the FDA ; a common fraction, etoricoxib ( Arcoxia , Merck), has been approved by the European regulatory book and is currently under discourse for FDA liking, and a musical interval, lumiracoxib ( Prexige ; Novartis), was recently approved in England and Mexico for the direction of acute and chronic pain and is also under selling discussion by the FDA.
Other pain relievers, such as aspirin, ibuprofen, and naproxen, cast not only COX-2 but also COX-1, a related enzyme.
COX-1 blocking action at law leads to psychological state of the appetite protective covering.
Therefore, the primary coil selling linear measure that Merck emphasized in its selling of Vioxx was the fact that it inhibits COX-2 and its painful inflammatory products while having no result on COX-1, thereby producing fewer ulcers and other gastrointestinal problems.
This is a part of article Chemical process of Action mechanism Taken from "Generic Arcoxia (Etoricoxib)" Information Blog